Gahan J. Pandina: Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial

Name: Gahan J. Pandina: Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial
SKU: pb-40-3-pandina
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

SKU: pb-40-3-pandina Categories: Psychopharmacology Bulletin, VOL 40 No. 3 Articles Tags: carla-m-canuso, gahan-j-pandina, generalized-anxiety-disorder, ibrahim-turkoz, mary-kujawa, md, mph, ms, phd, ramy-a-mahmoud, risperidone-adjunctive-treatment, selective-serotonin-receptor-inhibitors

Description

Gahan J. Pandina: Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial

Description

Gahan J. Pandina, PhD Link

NEGATIVE AND FAILED CLINICAL TRIAL REPORTS

Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial

Gahan J. Pandina, PhD, Carla M. Canuso, MD, Ibrahim Turkoz, MS, Mary Kujawa, MD, PhD, and Ramy A. Mahmoud, MD, MPH

Aysegul Yolga Tahiroglu, MD: Polypharmacy and EPS in a Child; A Case Report

Thomas J. Raedler, MD: Lithium-Induced Nephropathies

Trisha Suppes, MD, PhD: Awareness of Metabolic Concerns and Perceived Impact of Pharmacotherapy in Patients with Bipolar Disorder: A Survey of 500 US Psychiatrists

Robert MA Hirschfeld, MD: Defining the Clinical Course of Bipolar Disorder: Response, Remission, Relapse, Recurrence, and Roughening

Gahan J. Pandina: Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial

Description

Gahan J. Pandina, PhD Link

NEGATIVE AND FAILED CLINICAL TRIAL REPORTS

Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial

Gahan J. Pandina, PhD, Carla M. Canuso, MD, Ibrahim Turkoz, MS, Mary Kujawa, MD, PhD, and Ramy A. Mahmoud, MD, MPH

Related products

Aysegul Yolga Tahiroglu, MD: Polypharmacy and EPS in a Child; A Case Report

Thomas J. Raedler, MD: Lithium-Induced Nephropathies

Trisha Suppes, MD, PhD: Awareness of Metabolic Concerns and Perceived Impact of Pharmacotherapy in Patients with Bipolar Disorder: A Survey of 500 US Psychiatrists

Robert MA Hirschfeld, MD: Defining the Clinical Course of Bipolar Disorder: Response, Remission, Relapse, Recurrence, and Roughening